



Express Mail No.: **EV475141935US**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: Young et al.

Confirmation No.: 7010

Application No.: 09/724,531

Group Art Unit: 1648

Filed: November 28, 2000

Examiner: Stacy Brown Chen

For: METHODS OF  
ADMINISTERING/DOSING ANTI-RSV  
ANTIBODIES FOR PROPHYLAXIS AND  
TREATMENT

Attorney Docket No.: 10271-021-999  
CAM: 209073-999020

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. §1.56 AND §1.97**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 and §1.97 to inform the United States Patent and Trademark Office ("USPTO") of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicant hereby invite the Examiner's attention to references **A19, B08-B10 and C24-C30** listed on the attached form entitled "List of References Cited by Applicant." Copies of references **B08-B10** and **C24-C30** are enclosed herewith.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

This supplemental information disclosure statement is being filed before the first Office Action on the merits after the filing of a Request for Continued Examination under 37 C.F.R. §1.114 in connection with the subject application. Pursuant to 37 C.F.R. §1.97(b), Applicants believe that no fee is due in connection with the filing of this Supplemental Information Disclosure Statement. However, if any fee is required, please charge the amount any such fee to Jones Day deposit account no. 50-3013.


Respectfully submitted,

Date: November 23, 2005

Margaret B. Brivanlou 40,922  
For: Margaret B. Brivanlou (Reg. No.)

Jennifer J. Chineda 46,617  
By: Jennifer J. Chineda (Reg. No.)

**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6742  
(212) 901-9028



**LIST OF REFERENCES CITED BY APPLICANT**  
(Use several sheets if necessary)

ATTY DOCKET NO. <b>10271-021-999</b>	APPLICATION NO <b>09/724,531</b>
APPLICANT <b>Young et al.</b>	
FILING DATE <b>November 28, 2000</b>	GROUP <b>1648</b>

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A19	5,929,212	07/27/99	Adair et al			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
	B08	WO 99/28471	06/10/99	PCT			
	B09	WO 00/56771	09/28/00	PCT			
	B10	WO 00/73346	12/07/00	PCT			

**OTHER REFERENCES** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

C24	Balint and Larrick, 1993, "Antibody engineering by parsimonious mutagenesis." Gene. 137(1):109-118
C25	Bourgeois et al., "New peptides recognizing viral epitope with tropism to mucosa - useful for, e.g. diagnosing, preventing and treating viral infection(s)." GENESEQ database entry for Accession No: AAW70933; 10/14/98 and alignment with Seq ID No: 12 of US Serial No. 09/771,415
C26	Egan et al., 1999, "Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity." Arzneimittel-forschung. 49(9):779-790
C27	Love et al., 1993, "How the anti-(metal chelate) antibody CHA255 is specific for the metal ion of its antigen: X-ray structures for two Fab/hapten complexes with different metals in the chelate." Biochemistry. 32(41):10950-10959
C28	Sakurai et al., 1999, "Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines." J Virol. 73(4):2956-2962
C29	Schier et al., 1996, "Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection." J Mol Biol. 255(1):28-43
C30	Whitlow et al., 1995, "1.85 A structure of anti-fluorescein 4-4-20 Fab." Protein Eng. 8(8):749-761

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



11-25-05 IFW 1648

Express Mail No.: EV475141935US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Young et al. Confirmation No.: 7010

Serial No.: 09/724,531 Art Unit: 1648

Filed: November 28, 2000 Examiner: Stacey Brown Chen.

For: METHODS OF  
ADMINISTERING/DOSING ANTI-  
RSV ANTIBODIES FOR  
PROPHYLAXIS AND TREATMENT Attorney Docket No: 10271-021-999  
CAM: 209073-999020

**FEE TRANSMITTAL SHEET**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$0.00.

The claim amendment fee has been estimated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)	<input type="checkbox"/> SMALL ENTITY		<input checked="" type="checkbox"/> OTHER THAN A SMALL ENTITY	
CLAIMS REMAINING AFTER AMENDMENT	HIGHEST NO. PREVIOUSLY PAID	PRESENT EXTRA	RATE	ADDIT. FEE	OR	ADDIT. FEE
TOTAL 163 MINUS 318	0	x 9	\$ 0.00	X18	\$	
INDEP. 9 MINUS 38	0	x 43	\$ 0.00	x 86	\$	
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM			\$ 0.00		\$	
TOTAL			\$ 0.00	OR	TOTAL	\$

Please charge the required fee to Jones Day Deposit Account No. 50-3013. A copy of this sheet is enclosed.

Respectfully submitted,

Date: November 23, 2005

*Margaret B. Brivanlou* 40,922  
For: Margaret B. Brivanlou (Reg. No.)

*Jennifer J. Chheda* 46,617  
By: Jennifer J. Chheda (Reg. No.)

JONES DAY  
222 East 41<sup>st</sup> Street  
New York, New York 10017-6742  
(212) 901-9028